Featured Research

from universities, journals, and other organizations

New Link In The Chain Between Bacteria And Inflammatory Bowel Disease

Date:
October 8, 2006
Source:
Journal of Clinical Investigation
Summary:
Inflammatory bowel disease is caused by an inappropriate immune response to bacteria living naturally in the gut, but how bacteria trigger this is not known. A new study has now shown that mice lacking RELM-beta are protected from colitis induced by ingestion of dextran sodium sulfate. RELM-beta activated macrophages to produce pro-inflammatory factors; so, the authors of the study suggest that RELM-beta is one important link between bacteria and the onset of IBD.

Crohn's disease and ulcerative colitis are the most common forms of inflammatory bowel disease (IBD). Although IBD is thought to be caused by an inappropriate immune response to the bacteria living naturally in the gut, exactly how bacteria trigger this response is not known.

Now, in a study appearing online on October 5 in advance of publication in the November print issue of the Journal of Clinical Investigation, researchers from the University of Philadelphia have shown that mice lacking the protein RELM-beta are protected from colitis induced by ingestion of dextran sodium sulfate (DSS).

Previous studies have shown that bacteria in the gut induce cells of the intestine to produce RELM-beta. So, David Wu and colleagues set out to investigate whether this protein had a role in IBD. They found that mice lacking RELM-beta were protected from DSS-induced colitis and that RELM-beta was highly expressed in the colon of mice that spontaneously develop an IBD-like disease.

As RELM-beta was found to activate macrophages to produce pro-inflammatory factors both in vitro and in vivo, the authors suggest that RELM-beta is one important link between bacteria and the onset of IBD.


Story Source:

The above story is based on materials provided by Journal of Clinical Investigation. Note: Materials may be edited for content and length.


Cite This Page:

Journal of Clinical Investigation. "New Link In The Chain Between Bacteria And Inflammatory Bowel Disease." ScienceDaily. ScienceDaily, 8 October 2006. <www.sciencedaily.com/releases/2006/10/061006080454.htm>.
Journal of Clinical Investigation. (2006, October 8). New Link In The Chain Between Bacteria And Inflammatory Bowel Disease. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2006/10/061006080454.htm
Journal of Clinical Investigation. "New Link In The Chain Between Bacteria And Inflammatory Bowel Disease." ScienceDaily. www.sciencedaily.com/releases/2006/10/061006080454.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins